Sapphire® II 1.0-mm 球囊辅助微切割在球囊不可通过的慢性完全闭塞病变中的疗效和安全性。

Efficacy and safety of balloon-assisted microdissection with Sapphire® II 1.0-mm balloon in balloon-uncrossable chronic total occlusion lesions.

机构信息

Department of Cardiology, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical University, Beijing, China.

Department of Cardiology, Tongliao Hospital, Neimengu, China.

出版信息

J Int Med Res. 2020 Oct;48(10):300060520965822. doi: 10.1177/0300060520965822.

DOI:10.1177/0300060520965822

PMID:33103520

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7645396/

Abstract

OBJECTIVE

Earlier studies have shown that the balloon-assisted microdissection (BAM) technique is feasible using a 1.2- to 1.5-mm small balloon in balloon-uncrossable chronic total occlusion (CTO) lesions. This study was performed to assess the efficacy and safety of the BAM technique with a Sapphire® II 1.0-mm balloon.

METHODS

In this retrospective study, patients undergoing percutaneous coronary intervention for CTO were consecutively screened for balloon-uncrossable CTO lesions using BAM with the Sapphire® II 1.0-mm balloon. The patients' clinical and angiographic characteristics and procedural outcomes were collected for analyses.

RESULTS

Twenty-four balloon-uncrossable CTO lesions were identified. Most of the CTO lesions were located in the right coronary artery, followed by the left anterior descending artery and left circumflex artery. The mean Japanese Multicenter CTO Registry (J-CTO) and Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS CTO) scores were 1.96 and 1.38, respectively. The total technical success rates were 91.6% (22/24) and 75.00% (18/24) for the lesions that were successfully treated with BAM. No patients developed major complications with the exception of one patient who developed a femoral hematoma.

CONCLUSION

BAM with the Sapphire® II 1.0-mm balloon may be an effective and safe technique for balloon-uncrossable CTO lesions.

摘要

目的

早期研究表明，在球囊不可跨越的慢性完全闭塞（CTO）病变中使用 1.2-1.5mm 的小球囊，球囊辅助显微解剖（BAM）技术是可行的。本研究旨在评估使用 Sapphire® II 1.0mm 球囊的 BAM 技术的疗效和安全性。

方法

在这项回顾性研究中，连续筛选了接受经皮冠状动脉介入治疗（PCI）的 CTO 患者，使用 Sapphire® II 1.0mm 球囊进行 BAM 以评估球囊不可跨越的 CTO 病变。收集患者的临床和血管造影特征及手术结果进行分析。

结果

共发现 24 个球囊不可跨越的 CTO 病变。大多数 CTO 病变位于右冠状动脉，其次是左前降支和左回旋支。平均日本多中心 CTO 登记（J-CTO）和前瞻性全球慢性完全闭塞介入治疗登记（PROGRESS CTO）评分分别为 1.96 和 1.38。BAM 成功治疗的病变中，总技术成功率分别为 91.6%（22/24）和 75.00%（18/24）。除 1 例发生股血肿外，无患者发生重大并发症。